(Press-News.org) Results from the NRG Oncology Phase II NRG-GOG-0279 clinical study indicate that women with locally advanced squamous cell carcinoma of the vulva who received gemcitabine concurrently with cisplatin and intensity-modulated radiation therapy (IMRT) exhibited increased rate of pathologic complete responses (pCR). This is also the first clinical trial to standardize IMRT. These findings were presented during the Plenary Session at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
“Women with locally advanced vulvar cancer are currently treated with standard chemoradiation, which results in a high number of patients experiencing locoregional recurrence in their lifetime. NRG-GOG-0279 was designed to determine whether the addition of gemcitabine to cisplatin and higher doses of radiation administered with IMRT, could improve the efficacy of the treatment while avoiding added toxicity for these patients,” stated Neil S. Horowitz, MD, of the Brigham and Women’s Hospital and Harvard Medical School and the lead author of the NRG-GOG-0279 abstract.
NRG-GOG-0279 analyzed 52 eligible and treated women with locally advanced vulvar cancer (LAVC) that was not amendable to surgery. Patients received 64 Gy to the vulva and 50 or 64 Gy to the groins and low pelvis for positive nodes and unresectable nodes respectively. Cisplatin (40mg/m2) and gemcitabine (50mg/m2) were administered weekly throughout IMRT. Response was then assessed at 6 to 8 weeks following treatment.
NRG-GOG-0279 assessed pCR as the primary endpoint, with a main goal of improving pCR outcomes by 20% or more when compared to the pCR rate of 50% reported for the GOG-0205 trial. If successful, this would warrant further investigation into this study approach. The trial also evaluated complete clinical response (cCR), PFS, overall survival (OS), and adverse events as secondary endpoints.
Patients on the trial received a median of six cycles of gemcitabine and cisplatin. Of the 44 patients who had radiation therapy compliance reviewed 33 (75%) had high quality IMRT and 11 patients (25%) had minor deviations. Of the 44 evaluable patients, 38 patients achieved pCR (73.1%, 90% CI 61.2-83.0%) and 37 had cCR (71.2%, 90%CI 59.1-81.3%). At the median follow-up of 51 months, PFS at 12 months was 74% (90%CI 62.2-82.7%) and OS at 24 months was 69.6% (90%CI 57.4 – 79%). There was one grade 5 toxicity, 25 patients experienced grade 3 adverse events and 18 patients experienced grade 4 adverse events. Common grade 3 and 4 adverse events included radiation dermatitis, leukopenia, thrombocytopenia, and electrolyte abnormalities.
“While this approach improved survival and response outcomes for this population, it is important to note that future research is needed to find the ideal treatment regimen for this patient population to improve clinical outcomes further while minimizing toxicity,” Dr. Horowitz added.
This project was supported by grants U10CA180868 (NRG Oncology Operations) and U10CA180822 (NRG Oncology SDMC) from the National Cancer Institute (NCI).
Citation
Horowitz NS, Deng W, Monk BJ, Leath CA III, Peterson I, Dizon D, Miller A, Mayadev JS. A phase II trial evaluating cisplatin and gemcitabine concurrent with intensity-modulated radiation therapy (Imrt) in the treatment of locally advanced squamous cell carcinoma of the vulva: An NRG Oncology Group study. SGO (Society of Gynecologic Oncology).
About NRG Oncology
NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the legacy National Surgical Adjuvant Breast and Bowel Project (NSABP), Radiation Therapy Oncology Group (RTOG), and Gynecologic Oncology Group (GOG) programs. The research network seeks to conduct clinical trials with emphasis on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.
www.nrgoncology.org
END
The addition of gemcitabine with cisplatin and intensity-modulated radiation therapy improves outcomes for women with locally advanced vulvar cancer
2023-03-25
ELSE PRESS RELEASES FROM THIS DATE:
The utilization of atezolizumab as a primer for chemoradiation results in promising immune system alterations for women with locally advanced cervical cancer
2023-03-25
Locally advanced cervical cancer remains an area of high therapeutic need, with recent trials failing to demonstrate evidence of benefit from adjuvant chemotherapy or immune checkpoint blockade administered concurrent with chemoradiation. Results from the NRG-GY017 randomized trial comparing the anti-PD-L1 inhibitor atezolizumab before and concurrent with chemoradiation (CRT) indicated favorable outcomes for 2-year disease-free survival (DFS) and demonstrated evidence of improved immunogenicity with neoadjuvant atezolizumab in patients with locally advanced cervical cancer. These findings were presented during the Plenary Session at the Society of Gynecologic ...
Women are more likely to experience long-term anxiety after cardiac arrest than men
2023-03-25
Marseille, France – 26 March 2023: More than 40% of women report anxiety four months after a cardiac arrest compared with 23% of men, according to research presented today at ESC Acute CardioVascular Care 2023, a scientific congress of the European Society of Cardiology (ESC).1
“Cardiac arrest occurs with little or no warning and it’s common to feel anxious and low afterwards,” said study author Dr. Jesper Kjaergaard of Rigshospitalet - Copenhagen University Hospital, Denmark. “After the initial shock and confusion, patients and their families have an abrupt change in their way of life, with medical investigations ...
How one state beat national surgery opioid trends
2023-03-25
A statewide effort to treat the pain of surgery patients without increasing their risk of long-term dependence on opioids has paid off in Michigan, a study shows.
In less than two years, the effort led to a 56% reduction in the amount of opioids patients received after having six different common operations, and a 26% drop in the chance that they would still be filling opioid prescriptions months after their surgical pain should have eased.
Both of those drops beat national trends for similar patients, according to the new study published ...
Acquisitions can nix existing partnerships
2023-03-25
Business alliances are valuable because they help companies supplement critical skills, enter new markets, and gain competitive advantages.
In the pharmaceutical industry, strategic alliances are common because they help companies reduce risks and share the large R&D costs of bringing new drugs to market — like the partnership of Pfizer and BioNTech on vaccines. Such partnerships can take years to develop and are critical to a pharma company’s success.
But when biopharmaceutical companies merge, preserving their preexisting alliances isn’t always a priority, according to a new Texas McCombs study.
“High-performing alliances ...
Illinois Tech Assistant Professor Ren Wang receives prestigious National Science Foundation Award
2023-03-25
CHICAGO—March 24, 2023—Illinois Institute of Technology Assistant Professor Ren Wang has been honored with the National Science Foundation’s Computer and Information Science and Engineering Research Initiation Initiative (CRII) award. The two-year grant will support Wang’s groundbreaking research project, which aims to enhance the robustness of machine learning models by infusing key principles of the immune system into neural networks.
Wang’s innovative project, titled “Immune-Inspired Learning Foundations of Neural Network General Robustness,” not only advances the theory and ...
Antibiotics do not reduce risk of dying in adults hospitalised with common respiratory infections, suggests study
2023-03-25
**Note: the release below is a special early release from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023, Copenhagen, 15-18 April). Please credit the congress if you use this story**
Embargo: 2301H UK time Friday 24 March
Most patients admitted to hospital with acute viral respiratory infections are given antibiotics. Now new research to be presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark (15-18 April), suggests that prescribing antibiotic therapy to adults hospitalised with common viral respiratory infections such as influenza is unlikely to ...
Major European study confirms drop in suicides in last decade: may be linked to active measures to prevent suicide
2023-03-25
A major new study confirms the trend to fewer suicides in Europe. The findings show that suicide rates are down in 15 countries (including Germany and Italy), and stable elsewhere (including France, Spain and UK). Only Türkiye shows a significant increase. This work is presented for the first time at the European Congress of Psychiatry in Paris.
Suicide is one of the major causes of premature death, globally around 700,000 suicides are reported each year. European suicide rates have been generally ...
MSU researchers find clue to help plants grow with low phosphorus levels
2023-03-24
EAST LANSING, Mich. – Phosphorus is a natural mineral that is essential for plant growth and development, and Earth’s agricultural-grade phosphorus reserves are expected to be depleted in 50 to 100 years. A new discovery by researchers at Michigan State University and the Carnegie Institution for Science is changing their understanding of iron toxicity in plants caused by low phosphorus levels.
“Once the world’s supply is used up, we can’t make more phosphorus,” said Hatem Rouached, an assistant professor in MSU’s ...
New type of entanglement lets scientists ‘see’ inside nuclei
2023-03-24
The Science
Nuclear physicists have found a new way to see details inside atomic nuclei. They do so by tracking interactions between particles of light and gluons—the gluelike particles that hold together the building blocks of protons and neutrons. The method relies on harnessing a new type of quantum interference between two dissimilar particles. Tracking how these entangled particles emerge from the interactions lets scientists map out the arrangement of gluons.
The Impact
This technique is similar to how positron emission tomography (PET) scans image the brain and other body parts, but ...
NIH awards researchers $7.5 million to create data support center for opioid use disorder and pain management research
2023-03-24
WINSTON-SALEM, N.C. – March 24, 2023 – Researchers at Wake Forest University School of Medicine have been awarded a five-year, $7.5 million grant from the National Institutes of Health (NIH) Helping End Addiction Long-term (HEAL) initiative.
The NIH HEAL initiative, which launched in 2018, was created to find scientific solutions to stem the national opioid and pain public health crises. The funding is part of the HEAL Data 2 Action (HD2A) program, designed to use real-time data to guide actions and change processes toward reducing overdoses and improving opioid use disorder treatment ...